TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8536013
Drug: Lidocaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (5 ml intra-articular injection)
Study: 8536013
Drug: Saline with
Normalized name: CVS Saline with Aloe Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline with contrast dye (5 ml intra-articular injection)
Study: 3312048
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (IM)
Study: 24428972
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment in SS asthma
Study: 24428972
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment in SR asthma
Study: 19939870
Drug: Bupropion XR
Normalized name: bupropion Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion XR 150 mg
Study: 15979021
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR 75 mg
Study: 12372663
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of nicotine administered by nasal spray
Study: 10411037
Drug: Sacral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacral nerve stimulation (treatment group)
Study: 7419336
Drug: 80 kcal-PSMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kcal-PSMF (17 g protein=2.6 g N)
Study: 7419336
Drug: 180 kcal-PSMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 kcal-PSMF (40 g protein=6.4 g N, 2 g fat)
Study: 27667330
Drug: If participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: If participants who attempted vaccination had received the vaccine
Study: 15635208
Drug: Treatment (face
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (face immersion test)
Study: 12878742
Drug: EGF enemas
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EGF enemas (5 microg in 100 ml of inert carrier)
Study: 8803527
Drug: 76 mg
Normalized name: menthol 76 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 76 mg disodium monofluorophosphate (MFP, equivalent to 10.0 mg F- ion)
Study: 8803527
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg enteric-coated sodium fluoride (NaFor, equivalent of 11.3 mg F- ion)
Study: 8803527
Drug: 22.1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.1 mg sodium fluoride injection solution (NaFiv, equivalent to 10.0 mg F- ion)
Study: 1728720
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (25 U fast-acting insulin bolus followed by continuous infusion of 1 U/kg body weight for 1 hour)
Study: 6690344
Drug: sorbinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorbinil (250 mg o.d.)
Study: 6690344
Drug: sorbinil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorbinil (5 mg/kg)
Study: 30514364
Drug: Enriched flours
Normalized name: Flours
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched flours coupled with antibiotic treatment
Study: 23156122
Drug: Nutrition counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition counseling in the third trimester (education twice in the first month and once a month for the next 2 months)
Study: 21082306
Drug: Low-dose chlorhexidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chlorhexidine solution (CHX)
Study: 21082306
Drug: No chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chlorhexidine solution (no CHX)
Study: 15852426
Drug: Proton-pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitor (PPI) therapy
Study: 12769404
Drug: Topical colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical colchicine
Study: 11783194
Drug: Jianruling (JRL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianruling (JRL) treatment
Study: 73353
Drug: nalbuphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine (0.1 mg/kg)
Study: 1869004
Drug: pethidine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: pethidine (0.8 mg/kg)
Study: 6741674
Drug: Alcohol (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (two doses)
Study: 15889510
Drug: Medication (Control)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Control)
Study: 9327829
Drug: Vascular injury
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular injury treatment (angioplasty)
Study: 7695066
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) with birch pollen antigens in enterocoated capsules
Study: 3605563
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml 25% cocaine HCl combined with 0.1% adrenaline in paraffin paste
Study: 3605563
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml 25% cocaine HCl in paraffin paste
Study: 3605563
Drug: 4.0 ml
Normalized name: OCTINOXATE 7.5 mL in 100 mL / OCTISALATE 4.0 mL in 100 mL TOPICAL LIQUID [LONG LAST GLOSSWEAR SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 ml aqueous 4% cocaine HCl combined with 0.05% adrenaline
Study: 3605563
Drug: 4.0 ml
Normalized name: OCTINOXATE 7.5 mL in 100 mL / OCTISALATE 4.0 mL in 100 mL TOPICAL LIQUID [LONG LAST GLOSSWEAR SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 ml aqueous 4% cocaine HCl on ribbon gauze
Study: 27130202
Drug: Ipratropium bromide/albuterol
Normalized name: ipratropium bromide/albuterol sulfate 0.5 mg-2.5 mg/2.5 mL INHALATION VIAL, NEBULIZER (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium bromide/albuterol (CVT-MDI)
Study: 27130202
Drug: Albuterol (ALB-HFA)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (ALB-HFA)
Study: 24465438
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins (0.56 mg 5‐methyl‐tetrahydrofolate, 3 mg vitamin B6, 0.02 mg vitamin B12)
Study: 24465438
Drug: n‐3 fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 fatty acids (600 mg eicosapentaenoic and docosahexaenoic acids in a 2:1 ratio)
Study: 20664561
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (140 g/day)
Study: 20664561
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (50 g/day)
Study: 17978064
Drug: Oral azithromycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral azithromycin, 500 mg/day for 28 days
Study: 17978064
Drug: Intramuscular meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular meglumine antimoniate, 10 mg Sb/kg/day for 28 days
Study: 17978064
Drug: Intramuscular meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular meglumine antimoniate (for patients who failed azithromycin)
Study: 14762036
Drug: Warfarin (adjusted-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (adjusted-dose, target INR 1.4-2.8)
Study: 12649515
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg/d)
Study: 14762036
Drug: Both LA
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both LA and aCL antibodies positivity
Study: 11477460
Drug: Beta-carotene (8.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (8.2 mg)
Study: 7831627
Drug: Theophylline (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (oral, twice daily doses, trough serum concentrations between 8.4 and 13.5 mg/l)
Study: 7831627
Drug: Salbutamol (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (inhalation of 800 micrograms)
Study: 3241821
Drug: Aspirin 20
Normalized name: aspirin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 20 mg daily
Study: 3241821
Drug: Aspirin 1000
Normalized name: aspirin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1000 mg daily
Study: 24228447
Drug: 0.187% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.187% ropivacaine and fentanyl 3.2 microg x ml(‐1)
Study: 24228447
Drug: 0.187% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.187% levobupivacaine and fentanyl 3.2 microg ml(‐1)
Study: 18362823
Drug: Interview administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interview administration of FACT-G
Study: 18362823
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of FACT-G
Study: 19809337
Drug: Risperidone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (up to 6 mg/day)
Study: 11558625
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin B12 (Tricortin 1000)
Study: 9168442
Drug: Escalating doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of epirubicin
Study: 9168442
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of epirubicin
Study: 29320575
Drug: AZP-531 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZP-531 (3 mg for 50-70 kg and 4 mg for >70 kg body weight)
Study: 23251870
Drug: Armodafinil 150
Normalized name: armodafinil 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 150 mg
Study: 16974191
Drug: DHEA (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (200 mg/d)
Study: 18606587
Drug: Netilmicin once
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin once daily (5 mg/kg/die)
Study: 18606587
Drug: Netilmicin twice
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin twice daily (5 mg/kg/die)
Study: 15681986
Drug: Relaxation breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation breathing exercise (30 minutes daily for 6 weeks)
Study: 42425
Drug: Lorazepam 4
Normalized name: lorazepam 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 4 mg/70 kg
Study: 31888707
Drug: Internet-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Cognitive Behavioral Treatment (iCBT) added to treatment as usual (TAU)
Study: 28291859
Drug: Two interforaminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two interforaminal Straumann implants (Regular Neck, 4.1 mm diameter, 8 mm length) loaded with Locator attachments transforming preexisting inferior conventional denture into an IOD.
Study: 26296857
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4.4 g daily for 1 month)
Study: 19489491
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Omeprazole and Amoxicillin)
Study: 16261464
Drug: Landiolol (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (loading dose of 125 microg kg(‐1) min(‐1) for 1 min followed by an infusion at 40 microg kg(‐1) min(‐1) for 4 min)
Study: 9260344
Drug: No-treatment wait‐list
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment wait‐list control
Study: 3553281
Drug: Vinpocetine 10
Normalized name: vinpocetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinpocetine 10 mg three times a day for 30 days, then 5 mg three times a day for 60 days
Study: 25972286
Drug: Fidaxomicin 200
Normalized name: fidaxomicin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidaxomicin 200 mg
Study: 22191245
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy alone
Study: 19101237
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 1,000 ml/day of fluid intake, 120 mmol/day sodium, and 250 mg furosemide twice daily
Study: 19101237
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 1,000 ml/day of fluid intake, 120 mmol/day sodium, and 125 mg furosemide twice daily
Study: 19101237
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 1,000 ml/day fluid intake, 80 mmol/day sodium, and 250 mg furosemide twice daily
Study: 19101237
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: 1,000 ml/day fluid intake, 80 mmol/day sodium, and 125 mg furosemide twice daily
Study: 19101237
Drug: Group E:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group E: 2,000 ml/day fluid intake, 120 mmol/day sodium, and 250 mg furosemide twice daily
Study: 19101237
Drug: Group F:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group F: 2,000 ml/day fluid intake, 120 mmol/day sodium, and 125 mg furosemide twice daily
Study: 19101237
Drug: Group G:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G: 2,000 ml/day fluid intake, 80 mmol/day sodium, and 250 mg furosemide twice daily
Study: 19101237
Drug: Group H:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group H: 2,000 ml/day fluid intake, 80 mmol/day sodium, and 125 mg furosemide twice daily
Study: 15331895
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg intravenous Ketorolac
Study: 7691114
Drug: G-CSF +
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF + quinolone
Study: 23000049
Drug: Non-augmented group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-augmented group (fixed using LCP DF without augmentation)
Study: 18211656
Drug: Structured pharmaceutical
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured pharmaceutical care service (including education and introduction of intensive self‐monitoring)
Study: 16322118
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (50 mg daily) and methotrexate (2.5 mg twice daily on days 1 and 4)
Study: 16322118
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (50 mg daily) and methotrexate (2.5 mg twice daily on days 1 and 4) plus thalidomide (200 mg daily)
Study: 29020479
Drug: Topical silicone
Normalized name: silicones Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silicone gel applied after Er:YAG laser treatment
Study: 29020479
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied after Er:YAG laser treatment
Study: 26923831
Drug: Silicone intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone intranasal splints removed on the fifth postoperative day
Study: 26923831
Drug: Silicone intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone intranasal splints removed on the seventh postoperative day
Study: 26923831
Drug: Silicone intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone intranasal splints removed on the tenth postoperative day
Study: 24786930
Drug: Resistive home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resistive home exercise (12 weeks, 5 days/week) followed by twice-a-week home or gym exercise (12 weeks)
Study: 15037328
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily
Study: 9840102
Drug: Topical glucocorticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glucocorticosteroids (hydrocortisone acetate foam preparation, 100 mg b.i.d.)
Study: 1091216
Drug: Fluprednylidene acetate
Normalized name: fluprednidene
DrugBank: Fluprednidene acetate (DB14634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluprednylidene acetate cream applied once daily plus cream base of the same formulation twice daily
Study: 1091216
Drug: Fluprednylidene acetate
Normalized name: fluprednidene
DrugBank: Fluprednidene acetate (DB14634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluprednylidene acetate cream applied 3 times daily
Study: 1091216
Drug: Betamethasone 17-valerate
Normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 17-valerate cream applied 3 times daily
Study: 22884040
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment group
Study: 23563444
Drug: 2 hours
Normalized name: PATCH, TRANSDERMAL 72 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hours of daily patching with active vision therapy
Study: 23563444
Drug: 2 hours
Normalized name: PATCH, TRANSDERMAL 72 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hours of daily patching with placebo vision therapy
Study: 15559530
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor-based first line triple therapies
Study: 15559530
Drug: H2 blockers-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 blockers-based therapies
Study: 15559530
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor-based double combinations
Study: 15559530
Drug: Clarithromycin+amoxicillin/nitroimidazole combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin+amoxicillin/nitroimidazole combinations
Study: 15559530
Drug: Amoxicillin-nitroimidazole regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-nitroimidazole regimens
Study: 15559530
Drug: Quadruple therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapies (first-line)
Study: 15559530
Drug: Quadruple therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapies (second-line)
Study: 11426363
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (30,000 KIU/kg added to pump prime, 15,000 KIU/kg every hour during cardiopulmonary bypass)
Study: 7643542
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (AHT) - angiotensin converting enzyme inhibition for 6 (2 to 15) years
Study: 30812036
Drug: No mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mechanical bowel preparation (MBP)
Study: 30812036
Drug: Routine mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine mechanical bowel preparation (MBP)
Study: 9585392
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (ACEIs)
Study: 18559556
Drug: Curcumin 10
Normalized name: curcumin 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 10 g
Study: 18559556
Drug: Curcumin 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 12 g
Study: 16176340
Drug: Landiolol (short‐acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (short‐acting beta‐1‐adrenergic blocker)
Study: 2118879
Drug: Repeated application
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated application of the same dose
Study: 23758661
Drug: 2 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 minutes of daily progressive resistance training with elastic tubing
Study: 23758661
Drug: 12 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 minutes of daily progressive resistance training with elastic tubing
Study: 23758661
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving weekly information on general health
Study: 14985224
Drug: 400 micro
Normalized name: EM 2400 Micro Volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micro g folic acid
Study: 14985224
Drug: 416 micro
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 416 micro g [6S]-5-MTHF
Study: 14985224
Drug: 208 micro
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 208 micro g [6S]-5-MTHF
Study: 11134430
Drug: Recombinant granulocyte
Normalized name: Glycosylated recombinant granulocyte colony stimulating factor
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant granulocyte colony-stimulating factor (rG-CSF) 10 microgram/kg/day IV once daily for 3 days
Study: 8487664
Drug: HEPARIN
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HEPARIN
Study: 24439136
Drug: Tigecycline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (150 mg once-daily)
Study: 24439136
Drug: Ertapenem ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem ± vancomycin (1 g once-daily)
Study: 19128258
Drug: Topical basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical basic fibroblast growth factor (bFGF)
Study: 12525515
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus fluorouracil (FU)-leucovorin chemotherapy (431 patients)
Study: 8780417
Drug: Desipramine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (200 mg daily)
Study: 1363375
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of propranolol
Study: 1363375
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of diazepam
Study: 6469178
Drug: Maaloxan Suspension
Normalized name: alloxan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maaloxan Suspension
Study: 6469178
Drug: Kompensan‐S forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kompensan‐S forte Suspension
Study: 6469178
Drug: Solugastril 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solugastril 50 Gel
Study: 29318917
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (20-minute session) combined with manual therapy (15-minute session) and therapeutic exercise (15-minute session)